In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.

We constructed a modified RSV F protein, RSV-F005, to mimic the natural trimer conformation of the RSV F protein. The purified recombinant H-muad protein has been confirmed by TEM to form virus-like particles. The efficiency of H-muad to enhance mucosal immune responses was also fully evaluated in our mouse experiments with RSV candidate vaccine RSV-F005.

RSV vaccine is a brand new market segment. The treatment market of RSV is estimated to be reaching $2.3 billion in 2024.
The FDA has been very conservative in reviewingapproving new vaccine adjuvants due to concerns about inappropriate side effects. Our candidate adjuvant H-muad is non-activerelatively safe nanoparticles. The global market for vaccine adjuvants is estimated to increase from $470